The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of May 2016. This month there are three clinical guidelines and two technology appraisals that impact upon primary care.
The Dementia clinical guideline covers preventing, diagnosing, assessing and managing dementia in health and social care. The recommendation on prescribing medicines for Alzheimer’s disease was reviewed and partially updated.
The Crohn's Disease clinical guideline covers the management of Crohn’s disease in children, young people and adults. In this update a new recommendation on inducing remission was added.
The Psychosis and schizophrenia in children and young people clinical guideline covers recognising and managing psychosis and schizophrenia in children and young people. In this update a new recommendation was added on providing information about olanzapine when choosing antipsychotic medication for children and young people with a first episode of psychosis.
The Canagliflozin, dapagliflozin and empagliflozin technology appraisal recommends these drugs as monotherapy treatment as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
- a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
- a sulfonylurea or pioglitazone is not appropriate
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Bydureon device change||SMC Update - June 2016 »|